General AML

EBMT 2019 | Prevention of relapse following allogeneic stem cell transplantation using azacitidine in patients with high-risk AML

Philippa Redondo Joanna Nikitorowicz-Buniak , Apr 10, 2019

General AML

EBMT 2019 | Graft-versus-host disease prophylaxis with reduced intensity conditioning regimen combined with anti-thymocyte…

Zara Kassam , Apr 9, 2019

General AML

EBMT 2019 | Umbilical cord blood transplantation in adolescents and young adults with acute myeloid leukemia

Emily Smith , Apr 8, 2019

General AML

EBMT 2019 | No association between graft-versus-leukemia effect and graft-versus-host disease in patients with acute myeloid…

Emily Smith , Apr 8, 2019

IDH1/2

FDA grants ivosidenib (Tibsovo®), in combination with azacitidine, Breakthrough Therapy Designation for the treatment of…

Philippa Redondo , Apr 3, 2019

General AML

Paresh Vyas | EBMT 2019 | Leukemic stem cells and clonal structure in relapse following transplant

Paresh Vyas Emily Smith , Apr 1, 2019

General AML

EBMT 2019 | Autologous fecal microbiota transfer is safe and effective in patients with AML: results from the Odyssee trial

Philippa Redondo , Mar 29, 2019

General AML

Ali Bazarbachi | EBMT 2019 | Maintenance treatment after stem cell transplantation

Ali Bazarbachi Philippa Redondo , Mar 28, 2019